MX2021000954A - Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales. - Google Patents

Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.

Info

Publication number
MX2021000954A
MX2021000954A MX2021000954A MX2021000954A MX2021000954A MX 2021000954 A MX2021000954 A MX 2021000954A MX 2021000954 A MX2021000954 A MX 2021000954A MX 2021000954 A MX2021000954 A MX 2021000954A MX 2021000954 A MX2021000954 A MX 2021000954A
Authority
MX
Mexico
Prior art keywords
stem cells
cells enriched
functional mitochondria
increase therapy
mitochondrial
Prior art date
Application number
MX2021000954A
Other languages
English (en)
Spanish (es)
Inventor
Ohana Natalie Yivgi
Uriel Halavee
Shmuel Bukshpan
Noa Sher
Original Assignee
Minovia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minovia Therapeutics Ltd filed Critical Minovia Therapeutics Ltd
Publication of MX2021000954A publication Critical patent/MX2021000954A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0632—Cells of the oral mucosa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
MX2021000954A 2018-07-22 2019-07-22 Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales. MX2021000954A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701783P 2018-07-22 2018-07-22
PCT/IL2019/050828 WO2020021541A1 (en) 2018-07-22 2019-07-22 Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria

Publications (1)

Publication Number Publication Date
MX2021000954A true MX2021000954A (es) 2021-03-31

Family

ID=69181398

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000954A MX2021000954A (es) 2018-07-22 2019-07-22 Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.

Country Status (11)

Country Link
US (2) US20210322485A1 (https=)
EP (1) EP3823642A4 (https=)
JP (1) JP7633148B2 (https=)
KR (1) KR20210035829A (https=)
CN (1) CN112601532A (https=)
AU (1) AU2019311862B2 (https=)
BR (1) BR112021001010A2 (https=)
CA (1) CA3106188A1 (https=)
IL (1) IL280162B2 (https=)
MX (1) MX2021000954A (https=)
WO (1) WO2020021541A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US12551504B2 (en) 2018-07-22 2026-02-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
JP7458368B2 (ja) 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法
TWI789724B (zh) * 2020-03-20 2023-01-11 台灣粒線體應用技術股份有限公司 粒線體用於治療及/或預防肌腱受損或其相關疾病之用途
CA3172402A1 (en) * 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof
WO2021224920A1 (en) * 2020-05-05 2021-11-11 Pluristem Ltd. Methods and compositions for enrichment of target cells
AU2022211691A1 (en) * 2021-01-25 2023-08-10 Minovia Therapeutics Ltd. Identification of mitochondria-enriched cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
EP2150117A4 (en) * 2007-05-02 2011-10-05 Mclean Hospital Corp METHODS AND COMPOSITIONS FOR MITOCHONDRIA REPLACEMENT THERAPY
CN102266350A (zh) * 2011-07-20 2011-12-07 黄必录 逆转干细胞衰老的方案
CN102293178A (zh) * 2011-08-28 2011-12-28 黄必录 使个体去衰老的方法
CN103976935A (zh) * 2014-05-28 2014-08-13 广州市白云区天芳化妆品厂 一种抗衰原液及其制备方法
WO2016008937A1 (en) * 2014-07-16 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the intercellular transfer of isolated mitochondria in recipient cells
CN106795490B (zh) * 2014-09-11 2021-01-19 台湾粒线体应用技术股份有限公司 用线粒体特化细胞治疗神经退行性疾病的医药组合物
IL299482B2 (en) * 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
WO2018088874A1 (ko) 2016-11-14 2018-05-17 주식회사 파이안바이오테크놀로지 외래 미토콘드리아를 세포로 전달하는 방법
EP3549589A4 (en) 2016-11-30 2020-07-15 Paean Biotechnology Inc. PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA

Also Published As

Publication number Publication date
EP3823642A1 (en) 2021-05-26
US20240415894A1 (en) 2024-12-19
BR112021001010A2 (pt) 2021-04-20
IL280162B2 (en) 2026-01-01
WO2020021541A1 (en) 2020-01-30
KR20210035829A (ko) 2021-04-01
AU2019311862B2 (en) 2025-10-23
WO2020021541A9 (en) 2021-02-25
JP7633148B2 (ja) 2025-02-19
IL280162A (en) 2021-03-01
US20210322485A1 (en) 2021-10-21
CA3106188A1 (en) 2020-01-30
IL280162B1 (en) 2025-09-01
CN112601532A (zh) 2021-04-02
AU2019311862A1 (en) 2021-02-04
EP3823642A4 (en) 2022-05-18
JP2022519409A (ja) 2022-03-24

Similar Documents

Publication Publication Date Title
MX2021000954A (es) Terapia de aumento mitocondrial con celulas madre enriquecidas con mitocondrias funcionales.
CO2020009091A2 (es) Exosomas para inmunooncología y terapia antiinflamatoria
CO2017011564A2 (es) Métodos y kits para tratar la depresión
CL2018003702A1 (es) Formas sólidas cristalinas de un inhibidor de bet.
MX2021000955A (es) Terapia de incremento mitocondrial para enfermedades mitocondriales primarias.
AR118859A1 (es) Composiciones y métodos de fabricación de células t
BR112015023910A2 (pt) terapia envolvendo anticorpos contra claudin 18.2 para tratamento de câncer
MX2017005030A (es) Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
MX392752B (es) Terapia de combinacion para tratar cancer.
BR112014018429A8 (pt) Método para tratar um paciente que sofre de não-24, e, método para o tratamento crônico de não-24 em uma pessoa que está totalmente cega
MX2018001659A (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
AR085297A1 (es) METODOS PARA MEJORAR EL DESARROLLO DEL CEREBRO Y LA FUNCION COGNITIVA EN LOS QUE SE EMPLEA b-HIDROXI-b-METILBUTIRATO
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
MX365365B (es) Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
AR089852A1 (es) Anticuerpos anti-asic-1 y usos de los mismos
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
CL2019001586A1 (es) Insulina que contiene composiciones farmacéuticas.
MX2019003134A (es) Terapia de combinacion.
CO2023013465A2 (es) Composiciones y métodos para inhibir cetohexoquinasa (khk)
AR106364A1 (es) Derivados de insulina y sus usos médicos
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
CO2020007275A2 (es) Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas